Prevention, treatment and cure of HIV infection

RJ Landovitz, H Scott, SG Deeks - Nature Reviews Microbiology, 2023 - nature.com
The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection

P Thoueille, E Choong, M Cavassini… - Journal of …, 2022 - academic.oup.com
The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

A systematic review of the genetic mechanisms of dolutegravir resistance

SY Rhee, PM Grant, PL Tzou, G Barrow… - Journal of …, 2019 - academic.oup.com
Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …

Long-acting parenteral drug delivery systems for the treatment of chronic diseases

AB Jindal, AR Bhide, S Salave, D Rana… - Advanced Drug Delivery …, 2023 - Elsevier
The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …

Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery

SR Benhabbour, M Kovarova, C Jones… - Nature …, 2019 - nature.com
Here we report an ultra-long-acting tunable, biodegradable, and removable polymer-based
delivery system that offers sustained drug delivery for up to one year for HIV treatment or …

A year-long extended release nanoformulated cabotegravir prodrug

TA Kulkarni, AN Bade, B Sillman, BLD Shetty… - Nature materials, 2020 - nature.com
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to
monthly. However, dosing volumes, injection site reactions and health-care oversight are …

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

S Deodhar, B Sillman, AN Bade, SN Avedissian… - Nature …, 2022 - nature.com
Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18 …

Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges

V Agrahari, SM Anderson, MM Peet… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Aggregation-induced emission (AIE) fluorophores as imaging tools to trace the biological fate of nano-based drug delivery systems

Y Wang, Y Zhang, J Wang, XJ Liang - Advanced drug delivery reviews, 2019 - Elsevier
The vigorous development of nanotechnology has been accompanied by an equally strong
interest and research efforts in nano-based drug delivery systems (NDDSs). However, only a …

Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP)

LM Johnson, SA Krovi, L Li, N Girouard, ZR Demkovich… - Pharmaceutics, 2019 - mdpi.com
Long-acting (LA) HIV pre-exposure prophylaxis (PrEP) offers the potential to improve
adherence by lowering the burden of daily or on-demand regimens of antiretroviral (ARV) …